Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial

Benzinga 2025-10-22

Views 47

Minerva Neurosciences secured up to $200M in funding to advance its schizophrenia drug roluperidone. The financing follows FDA approval of its Phase 3 trial plan, aiming to treat negative symptoms unmet by current therapies.
Show more

Share This Video


Download

  
Report form
RELATED VIDEOS
La biotech Innate Pharma a signé un partenariat majeur avec AstraZeneca: Hervé Brailly - 24/04
play
11:06

La biotech Innate Pharma a signé un partenariat majeur avec AstraZeneca: Hervé Brailly - 24/04
Internet Week NY today, biotech & pharma tomorrow
play
01:36

Internet Week NY today, biotech & pharma tomorrow
[PDF] Biotech/Pharma/Medical Devices 2015 Directory of Venture Capital/Private Equity (Job
play
00:22

[PDF] Biotech/Pharma/Medical Devices 2015 Directory of Venture Capital/Private Equity (Job
BWT Pharma & Biotech providing Clean Utility Systems for Purified Water (Exhibitors TV @ Health Asia 2013)
play
02:33

BWT Pharma & Biotech providing Clean Utility Systems for Purified Water (Exhibitors TV @ Health Asia 2013)
Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
play
00:43

Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Biotech: Focus sur Genfit et Innate Pharma: Arnaud Guerin – 27/04
play
10:50

Biotech: Focus sur Genfit et Innate Pharma: Arnaud Guerin – 27/04
Schizophrenia Drugs (Zyprexa, Risperdal, Seroquel) FDA ...
play
06:00

Schizophrenia Drugs (Zyprexa, Risperdal, Seroquel) FDA ...
'We Want To Light A Fire Under Biotech': RFK Jr. Defends Layoffs At FDA
play
05:14

'We Want To Light A Fire Under Biotech': RFK Jr. Defends Layoffs At FDA
Biotech and pharma M&A to remain robust
play
01:35

Biotech and pharma M&A to remain robust
Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
play
00:49

Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Guillaume Bayre (BFM Bourse) : La pandémie rebat les cartes dans la pharma, manquant un point d'inflexion pour différentes entreprises biotechs - 02/12
play
08:04

Guillaume Bayre (BFM Bourse) : La pandémie rebat les cartes dans la pharma, manquant un point d'inflexion pour différentes entreprises biotechs - 02/12
This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment
play
16:00

This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment